Drug Profile
Briquilimab - Jasper Therapeutics
Alternative Names: AMG-191; JSP-191Latest Information Update: 25 Mar 2024
Price :
$50
*
At a glance
- Originator Amgen; National Heart, Lung and Blood Institute; Stanford University
- Developer Amgen; AVROBIO; Jasper Therapeutics
- Class Anti-inflammatories; Antianaemics; Antineoplastics; Immunotherapies; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Proto oncogene protein c-kit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Chronic urticaria
- Phase I Myelodysplastic syndromes
- Preclinical Anaphylaxis; Asthma; Fabry's disease; Gaucher's disease
- Discontinued Inflammation
Most Recent Events
- 19 Mar 2024 Phase-I/II clinical trials in Chronic-urticaria in European Union (SC)
- 04 Mar 2024 Jasper Therapeutics plans a phase Ib/IIa SPOTLIGHT trial for Chronic urticaria in European Union (SC) in second-half of 2024
- 04 Mar 2024 Jasper Therapeutics plans to initiate a new clinical program in at least one additional mast cell driven indication later 2024